UPDATE : Monday, June 17, 2019
상단여백
Korean biosimilars take on original drugs in Europe by Jeong Sae-im 2019-06-17 15:26
AstraZeneca to invest $630 million in Korean biohealth sector by Kim Yun-mi 2019-06-17 11:33
Daewoong to develop hearing loss treatment using ion-channel platform tech by Lee Han-soo 2019-06-14 17:27
Lilly, AbbVie unveil new data for psoriasis treatment at global meet by Lee Han-soo 2019-06-14 14:26
LSK Global PS wins international recognition in clinical data management by Lee Hye-seon 2019-06-13 14:30
라인
‘Many drugs won Chinese approval without review suspension’ by Jeong Sae-im 2019-06-13 11:26
Daewoong’s botulinum toxin hits a snag in European approval by Jeong Sae-im 2019-06-12 16:50
Novo Nordisk’s Saxenda dominates local obesity market by Lee Han-soo 2019-06-12 14:16
Forxiga prevents kidney disease in diabetes patients by Kim Yun-mi 2019-06-11 15:40
‘Medytox got review suspension in China only once’ by Jeong Sae-im 2019-06-11 10:50
라인
[ASCO 2019] Imfinzi 1st IO to report 3-year OS in unresectable stage III NSCLC by Lee Han-soo, KBR Correspondent 2019-06-11 08:00
SCM, T&R to develop tissue regeneration, therapy products by Lee Han-soo 2019-06-10 17:50
Regulator OKs AstraZeneca's Fasenra as additional therapy for severe asthma by Lee Han-soo 2019-06-10 17:10
CJ HealthCare to invest ₩100 billion in new IV fluid factory by Jeong Sae-im 2019-06-10 16:17
Hanmi unveils strong pipeline candidates in US diabetes meet by Lee Han-soo 2019-06-10 15:07
라인
Medytox’ botulinum toxin may face approval delay in China by Jeong Sae-im 2019-06-10 13:55
Daewoong joins fray to develop rheumatoid arthritis drug by Lee Hye-seon 2019-06-07 11:29
[ASCO 2019] 'Ibrance brings hopes to neglected premenopausal breast cancer patients' by Lee Han-soo, KBR Corresponden 2019-06-05 11:33
[ASCO 2019]'Belvarafenib confirms efficacy for solid cancer without approved treatment' by Lee Han-soo, KBR Correspondent 2019-06-05 11:29
FDA OKs phase-1 trial for Yuhan’s investigational lung cancer drug by Jeong Sae-im 2019-06-04 14:21
여백
여백
여백
Back to Top